Tuesday, May 14, 2024

🌎 Amicus Therapeutics Upgraded, BioNTech Initiated, CRH Initiated and more...

Ratings changes for Amicus Therapeutics, BioNTech, Fortrea, Aethlon Medical, Perion Network, Payoneer Global, Chord Energy and more...Upgrade to MarketBeat All Access to get early delivery, personalized stock alerts, portfolio monitoring tools, and more. Start Your Free Trial.
Unsubscribe.
MarketBeat Daily Ratings
May 14th, 2024
S and P pricesDow pricesQQQ prices
Follow MarketBeat on Twitter Join the MarketBeat Facebook Group Subscribe on YouTube 

Today's Top Stories
On Shares Move Higher in Race to a New All-Time High
Sony Group, The Container Store rise; Alibaba, Smart Sand fall, Tuesday, 5/14/2024
Gold's Price Surge: What It Means for You (Priority Gold)
What Wall Street Doesn't Want You to Know About Alibaba Stock
Fed's Powell downplays potential for a rate hike despite higher price pressures
Dutch Bros Gives Investors More Bang for the Buck than Starbucks
Czech power company CEZ reports net profit of $592 million in Q1, up by a quarter year-on-year
Claim Your Complimentary Bitcoin Reward (Crypto Swap Profits)
Home Depot: Earnings Mixed, Wait to Buy the Dip
Stock market today: Stocks edge higher on Wall Street, adding to gains for May
Crypto Miners Strike Gold in AI: Stocks to Watch
Xi's visit to Hungary and Serbia brings new Chinese investment and deeper ties to Europe's doorstep
Lucid's Stock Price Still in Reverse
Quick Links

Your Watchlist (Manage Your Watchlist and Monitor Your Portfolio)

Analysts' Upgrades
  • Atmos Energy (NYSE:ATO) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $132.00 price target on the stock, up previously from $130.00. This represents a 13.0% upside from the current price of $116.85.
  • Enhabit (NYSE:EHAB) was upgraded by analysts at SVB Leerink LLC from an "underperform" rating to a "market perform" rating. They now have a $8.50 price target on the stock. This represents a 6.1% downside from the current price of $9.05.
  • Edison International (NYSE:EIX) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $86.00 price target on the stock, up previously from $72.00. This represents a 15.2% upside from the current price of $74.67.
  • Edwards Lifesciences (NYSE:EW) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating.The current price is $85.33.
  • Expeditors International of Washington (NASDAQ:EXPD) was upgraded by analysts at BNP Paribas from an "underperform" rating to a "neutral" rating. They now have a $112.00 price target on the stock. This represents a 5.1% downside from the current price of $117.96.
  • Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock. This represents a 40.5% upside from the current price of $9.25.
  • Fortrea (NASDAQ:FTRE) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $36.00 price target on the stock, down previously from $45.00. This represents a 23.3% upside from the current price of $29.19.
  • Newell Brands (NASDAQ:NWL) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $8.00 price target on the stock. This represents a 7.3% downside from the current price of $8.63.
  • Planet Fitness (NYSE:PLNT) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $78.00 price target on the stock, up previously from $68.00. This represents a 17.8% upside from the current price of $66.19.
  • Boston Beer (NYSE:SAM) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $360.00 price target on the stock, up previously from $335.00. This represents a 26.2% upside from the current price of $285.24.
  • Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $180.00 price target on the stock. This represents a 37.1% upside from the current price of $131.30.
  • Neuronetics (NASDAQ:STIM) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.The current price is $2.49.
  • VTEX (NYSE:VTEX) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $9.00 price target on the stock. This represents a 27.7% upside from the current price of $7.05.
  • Expro Group (NYSE:XPRO) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $27.00 price target on the stock, up previously from $18.00. This represents a 27.8% upside from the current price of $21.12.
  • View today's most recent analysts' upgrades at MarketBeat.com right arrow


Analysts' Downgrades
  • AirSculpt Technologies (NASDAQ:AIRS) was downgraded by analysts at SVB Leerink LLC from an "outperform" rating to a "market perform" rating. They now have a $5.00 price target on the stock, down previously from $8.25. This represents a 11.6% upside from the current price of $4.48.
  • Augmedix (NASDAQ:AUGX) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $1.50 price target on the stock, down previously from $5.00. This represents a 27.1% upside from the current price of $1.18.
  • Augmedix (NASDAQ:AUGX) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. They now have a $5.00 price target on the stock. This represents a 323.7% upside from the current price of $1.18.
  • Jackson Financial (NYSE:JXN) was downgraded by analysts at Keefe, Bruyette & Woods from an "outperform" rating to a "market perform" rating.The current price is $74.96.
  • Inotiv (NASDAQ:NOTV) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $3.75 price target on the stock, down previously from $11.50. This represents a 76.1% upside from the current price of $2.13.
  • Shimmick (NASDAQ:SHIM) was downgraded by analysts at Craig Hallum from a "buy" rating to a "hold" rating.The current price is $2.76.
  • Shimmick (NASDAQ:SHIM) was downgraded by analysts at Roth Mkm from a "buy" rating to a "neutral" rating. They now have a $3.50 price target on the stock, down previously from $9.00. This represents a 26.8% upside from the current price of $2.76.
  • View today's most recent analysts' downgrades at MarketBeat.com right arrow


Analysts' New Coverage
  • Arcellx (NASDAQ:ACLX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $85.00 price target on the stock. This represents a 70.5% upside from the current price of $49.86.
  • Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) is now covered by analysts at Stephens. They set an "overweight" rating and a $25.00 price target on the stock. This represents a 151.3% upside from the current price of $9.95.
  • BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $50.00 price target on the stock. This represents a 73.7% upside from the current price of $28.78.
  • BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock. This represents a 41.7% upside from the current price of $79.75.
  • BioNTech (NASDAQ:BNTX) is now covered by analysts at Evercore ISI. They set an "inline" rating and a $100.00 price target on the stock. This represents a 9.0% upside from the current price of $91.78.
  • Blueprint Medicines (NASDAQ:BPMC) is now covered by analysts at Stephens. They set an "overweight" rating and a $140.00 price target on the stock. This represents a 31.8% upside from the current price of $106.24.
  • Perspective Therapeutics (NYSEAMERICAN:CATX) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $3.00 price target on the stock.
  • CI&T (NYSE:CINT) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $4.20 price target on the stock. This represents a 19.3% upside from the current price of $3.52.
  • CRH (NYSE:CRH) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $110.00 price target on the stock. This represents a 33.5% upside from the current price of $82.42.
  • CEMEX (NYSE:CX) is now covered by analysts at Royal Bank of Canada. They set an "underperform" rating and a $9.00 price target on the stock. This represents a 14.2% upside from the current price of $7.88.
  • Delcath Systems (NASDAQ:DCTH) is now covered by analysts at Stephens. They set an "overweight" rating and a $25.00 price target on the stock. This represents a 249.7% upside from the current price of $7.15.
  • The Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) is now covered by analysts at Redburn Atlantic. They set a "neutral" rating and a $90.00 price target on the stock. This represents a 5.5% downside from the current price of $95.20.
  • Elevation Oncology (NASDAQ:ELEV) is now covered by analysts at Stephens. They set an "overweight" rating and a $8.00 price target on the stock. This represents a 115.6% upside from the current price of $3.71.
  • Exelixis (NASDAQ:EXEL) is now covered by analysts at Stephens. They set an "equal weight" rating and a $23.00 price target on the stock. This represents a 10.5% upside from the current price of $20.81.
  • Inovio Pharmaceuticals (NASDAQ:INO) is now covered by analysts at Stephens. They set an "overweight" rating and a $20.00 price target on the stock. This represents a 76.2% upside from the current price of $11.35.
  • Manhattan Associates (NASDAQ:MANH) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $260.00 price target on the stock. This represents a 20.6% upside from the current price of $215.63.
  • Moderna (NASDAQ:MRNA) is now covered by analysts at Evercore ISI. They set an "in-line" rating and a $120.00 price target on the stock. This represents a 6.9% downside from the current price of $128.86.
  • Neurocrine Biosciences (NASDAQ:NBIX) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $175.00 price target on the stock. This represents a 29.7% upside from the current price of $134.96.
  • Nurix Therapeutics (NASDAQ:NRIX) is now covered by analysts at Stephens. They set an "overweight" rating and a $20.00 price target on the stock. This represents a 34.1% upside from the current price of $14.91.
  • Orion Group (NYSE:ORN) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $14.00 price target on the stock. This represents a 59.5% upside from the current price of $8.78.
  • Regeneron Pharmaceuticals (NASDAQ:REGN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $1,150.00 price target on the stock. This represents a 17.5% upside from the current price of $979.11.
  • Sensei Biotherapeutics (NASDAQ:SNSE) is now covered by analysts at Stephens. They set an "overweight" rating and a $5.00 price target on the stock. This represents a 222.6% upside from the current price of $1.55.
  • SPS Commerce (NASDAQ:SPSC) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $220.00 price target on the stock. This represents a 11.9% upside from the current price of $196.63.
  • Seagate Technology (NASDAQ:STX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $110.00 price target on the stock. This represents a 15.4% upside from the current price of $95.32.
  • Veru (NASDAQ:VERU) is now covered by analysts at B. Riley. They set a "buy" rating and a $5.00 price target on the stock. This represents a 244.8% upside from the current price of $1.45.
  • Vermilion Energy (NYSE:VET) (TSE:VET) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock.The current price is $12.02.
  • Western Digital (NASDAQ:WDC) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $90.00 price target on the stock. This represents a 24.5% upside from the current price of $72.28.
  • Weatherford International (NASDAQ:WFRD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $155.00 price target on the stock. This represents a 24.8% upside from the current price of $124.23.
  • View today's most recent analysts' new coverage at MarketBeat.com right arrow

Upgrade Your Subscription
Manage Your Watchlist
Join Our Facebook Group

Thank you for subscribing to MarketBeat!
We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
 
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.
 
© 2006-2024 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.
 
Today's Bonus Content: 2024's Must-Watch Stocks! (Click to Opt-in)
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

The Best of Retail: Fashion Adapts to a Tough Reality

BoF is away for its annual break until 2nd January. In the meantime, we invite you to explore highlights of our news and analysis from t...